
MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

